These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of vitiligo with psoralen derivatives. GEORGE WM; BURKS JW AMA Arch Derm; 1955 Jan; 71(1):14-8. PubMed ID: 13217464 [No Abstract] [Full Text] [Related]
3. The treatment of vitiligo with psoralen derivatives. LEVAI M AMA Arch Derm; 1958 Nov; 78(5):597-606. PubMed ID: 13582205 [No Abstract] [Full Text] [Related]
4. Hydrocortisone ointment in psoralen-treated vitiligo; effect in preventing dermatitis. GEORGE W; BURKS JW AMA Arch Derm; 1955 Nov; 72(5):458-61. PubMed ID: 13257922 [No Abstract] [Full Text] [Related]
5. [Experience in the use of a psoberan preparation in patients with vitiligo and alopecia]. Braĭtsev AV Vestn Dermatol Venerol; 1975 Sep; (9):53-5. PubMed ID: 1231363 [No Abstract] [Full Text] [Related]
6. Mechanism of psoralen photosensitization and in vivo biological action spectrum of 8-methoxypsoralen. PATHAK MA J Invest Dermatol; 1961 Nov; 37():397-407. PubMed ID: 14484337 [No Abstract] [Full Text] [Related]
7. A comparative clinical evaluation of trimethylpsoralen, psoralen and 8-methoxypsoralen in treating vitiligo. Sehgal VN Int J Dermatol; 1975 Apr; 14(3):205-8. PubMed ID: 1126780 [TBL] [Abstract][Full Text] [Related]
8. The psoralens. An historical perspective. Benedetto AV Cutis; 1977 Oct; 20(4):469-71. PubMed ID: 338258 [No Abstract] [Full Text] [Related]
10. [NEW SOVIET DRUGS, AMMIFURIN AND BEROXAN, FOR THE TREATMENT OF ALOPECIA AREATA AND VITILIGO]. VINOKUROV IN Vestn Dermatol Venerol; 1963 Oct; 37():10-4. PubMed ID: 14130948 [No Abstract] [Full Text] [Related]
11. Psoralen and bergapten: in silico metabolism and toxicophoric analysis of drugs used to treat vitiligo. da Silva VB; Kawano DF; Carvalho I; da Conceição EC; de Freitas O; da Silva CH J Pharm Pharm Sci; 2009; 12(3):378-87. PubMed ID: 20067712 [TBL] [Abstract][Full Text] [Related]
13. Electrophoretic studies of serum proteins in vitiligenous patients treated with oral psoralens and ultra-violet irradiation. EL-HEFNAWI H; EL-HAWARY MF; RASHEED A J Invest Dermatol; 1963 Feb; 40():111-9. PubMed ID: 13962712 [No Abstract] [Full Text] [Related]
14. Results in the treatment of vitiligo with 8-methoxypsoralen. SHELDON SA; HARRELL ER; CURTIS AC AMA Arch Derm; 1956 Jul; 74(1):9-13. PubMed ID: 13325954 [No Abstract] [Full Text] [Related]
15. The treatment of vitiligo with 8-methoxypsoralen. ELLIOTT JA South Med J; 1956 Jul; 49(7):691-7. PubMed ID: 13337429 [No Abstract] [Full Text] [Related]
16. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. Pathak MA; Mosher DB; Fitzpatrick TB Natl Cancer Inst Monogr; 1984 Dec; 66():165-73. PubMed ID: 6531024 [TBL] [Abstract][Full Text] [Related]
17. Local application of 8-methoxypsoralen in vitiligo. KELLY EW; PINKUS H J Invest Dermatol; 1955 Dec; 25(6):453-6. PubMed ID: 13286532 [No Abstract] [Full Text] [Related]
18. Clinical and experimental studies with 8-methoxypsoralen in vitiligo. LERNER AB; DENTON CR; FITZPATRICK TB J Invest Dermatol; 1953 Apr; 20(4):299-314. PubMed ID: 13052979 [No Abstract] [Full Text] [Related]
19. Identification of psoralen, 8-methoxypsoralen, isopimpinellin, and 5,7-dimethoxycoumarin in Pelea anisata H. Mann. Yoke Marchant Y; Turjman M; Flynn T; Balza F; Mitchell JC; Towers GH Contact Dermatitis; 1985 Apr; 12(4):196-9. PubMed ID: 4017567 [TBL] [Abstract][Full Text] [Related]